A vitamin C supplement that supports skin that glows from the inside
How much should I expect to pay for Mounjaro
GLP-1 receptor agonists, offering clinically proven and durable weight-loss outcomes, are thus positioned to capture expanding demand in obesity management, driving market growth globally and complementing their use in diabetes care
James S, Christoffersen AD, David J-P, et al
Many of us are seeing patients on GLP-1 medications report less interest in drinking or fewer cravings to use drugs
degludec assoc with: Liver fat content (LFC) 18-28% Both in either HbA1c or weight assoc with Both the visceral & subcutaneous abdominal fat equally ALT 4-22% AST 10-19% SURPASS-3 MRI trial (3/3) tirzepatide (particularly 10-15mg doses) looks to be possible treatments for #NAFLD #NASH, as well as #type2diabetes ongoing liver outcome RCT with liver biopsy clinicaltrials.gov/ct2/show/NCT04 SURPASS-3 CGM (1/2) another sub-study of SURPASS-3 (n=243) Dexcom G6 CGM used 1ry outcome - Time within Tight Target range 3.9-7.8 mmol/mol (71-140 mg/dL) at 24 + 52w % time within standard target range 3.9-10 mmol/mol (71-180 mg/dL) at 52w Presented by @TBattelino SURPASS - CGM (2/2) tirzepatide treatment assoc with: Marked in Tight TIR compared to ins